Edition:
United States

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

155.90USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$155.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
125,996
52-wk High
$164.00
52-wk Low
$34.58

Chart for

About

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290... (more)

Overall

Beta: --
Market Cap(Mil.): $8,230.41
Shares Outstanding(Mil.): 4.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage:

Feb 08 2018

BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China

* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZA® (AZACITIDINE FOR INJECTION) IN CHINA

Feb 05 2018

BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:

Jan 31 2018

BRIEF-BeiGene prices follow-on offering of 7.4 mln American depositary shares at $101 per ADS

* ‍PRICING OF FOLLOW-ON PUBLIC OFFERING OF 7. 4 MILLION AMERICAN DEPOSITARY SHARES AT A PRICE TO PUBLIC OF $101.00 PER ADS​ Source text for Eikon: Further company coverage:

Jan 17 2018

BRIEF-Beigene Announces Proposed Public Offering

* BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​

Jan 16 2018

BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab

* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB

Jan 09 2018

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

Jan 08 2018

BRIEF-Beigene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-BeiGene Initiates Pivotal Trial Of PARP Inhibitor Pamiparib In China

* BEIGENE INITIATES PIVOTAL TRIAL OF PARP INHIBITOR PAMIPARIB (BGB-290) IN CHINA IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:

Dec 18 2017

BRIEF-Beigene expands global pivotal program for BTK inhibitor BGB-3111

* Beigene expands global pivotal program for BTK inhibitor BGB-3111

Nov 13 2017

Earnings vs. Estimates